Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil (2021)
- Authors:
- USP affiliated authors: SOUZA, CACILDA DA SILVA - FMRP ; ROMITI, RICARDO - FM
- Unidades: FMRP; FM
- DOI: 10.1016/j.jaad.2021.06.375
- Assunto: PSORÍASE
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2021
- Source:
- Título: Journal of the American Academy of Dermatology
- ISSN: 0190-9622
- Volume/Número/Paginação/Ano: v. 85, n. 3, suppl., res. 26197, p. AB88, 2021
- Conference titles: American Academy of Dermatology Virtual Meeting Experience (AAD VMX)
- Status:
- Nenhuma versão em acesso aberto identificada
-
ABNT
CESTARI, Tania Ferreira et al. Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil. Journal of the American Academy of Dermatology. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jaad.2021.06.375. Acesso em: 15 abr. 2026. , 2021 -
APA
Cestari, T. F., Silva-Souza, C., Azulay-Abulafia, L., Romiti, R., Carvalho, A. V. E. de, Castro, C. C. S. de, et al. (2021). Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil. Journal of the American Academy of Dermatology. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.jaad.2021.06.375 -
NLM
Cestari TF, Silva-Souza C, Azulay-Abulafia L, Romiti R, Carvalho AVE de, Castro CCS de, Marques SA, Antonio JR, Fabrício LHZ, Kalabic J, Oyafuso LKM. Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil [Internet]. Journal of the American Academy of Dermatology. 2021 ; 85( 3): AB88.[citado 2026 abr. 15 ] Available from: https://doi.org/10.1016/j.jaad.2021.06.375 -
Vancouver
Cestari TF, Silva-Souza C, Azulay-Abulafia L, Romiti R, Carvalho AVE de, Castro CCS de, Marques SA, Antonio JR, Fabrício LHZ, Kalabic J, Oyafuso LKM. Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil [Internet]. Journal of the American Academy of Dermatology. 2021 ; 85( 3): AB88.[citado 2026 abr. 15 ] Available from: https://doi.org/10.1016/j.jaad.2021.06.375 - Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT)
- Alopecia de tração
- Eflúvio telógeno
- Alopecia areata
- Líquen plano pilar (líquen plano pilar clássico, alopecia fibrosante frontal e Síndrome de Graham-Little-Piccardi-Lassueur)
- Dermatose pustular erosiva do couro cabeludo
- Foliculite dissecante
- Lúpus eritematoso crônico
- Prurido
- The association between psoriasis and health-related quality of life, work productivity, and healthcare resource use in Brazil
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003231591.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
